logo
Beyond HumanBig PictureCatalystsConnected WorldExchangeMarketing MixNew MoneyNew SchoolPeople SciencePulse

Life in 2030, Episode 2, full interview: Ken Mulvany, Founder, BenevolentAI

Kenneth Mulvany

BenevolentAI want to use AI to help researchers identify possible cures to diseases more quickly.

According to the Association of the British Pharmaceutical Industry it costs £1.12 billion and up to 12 years to develop a single drug. Kenneth Mulvany, founder of BenevolentAI, the largest privately-held artificial intelligence company in Europe, wondered whether AI could speed this up to create more cures for previously thought incurable diseases. Drug discovery is, after all, a complicated business. The problem is making sense of the enormous amounts of data available to help researchers better inform the process.

Kenneth spoke with Manu Gupta, Hot Topics Contributing Editor and the series lead for Life In 2030.

CHANNELS